New health guidance on breast cancer

November 21, 2017, Queen Mary, University of London
Credit: Queen Mary, University of London

In their draft guidance, the National Institute for Health and Care Excellence (NICE) said that postmenopausal women with a family history of breast cancer should now be offered the drug anastrozole, and not tamoxifen, to help prevent the onset of the disease.

Anastrozole works by preventing the body from making oestrogen - a hormone that fuels many breast cancers.

The IBIS-II trial, led by QMUL's Wolfson Institute of Preventive Medicine, looked at almost 4,000 postmenopausal women at of with half being given daily and half given a placebo.

The researchers found that participants being treated with anastrozole were 53 per cent less likely to develop breast cancer than those on placebo, and that anastrozole was more effective than previous drugs such as tamoxifen, with fewer side effects.

Based on this research, NICE has now recommended that the , which costs four pence a day, is offered for five years to women at high risk of breast cancer in England, unless they have severe osteoporosis. Clinicians should also consider offering it to women at moderately increased risk of breast cancer.

Professor Jack Cuzick from QMUL said: "This is an incredibly important development in breast cancer prevention. Since our discovery that anastrozole is more effective and has fewer side effects than tamoxifen, we have known that it should be the drug of choice for reducing in postmenopausal women who are predisposed to developing the disease. Tamoxifen remains the drug of choice for premenopausal women.

"We are delighted that NICE have now added anastrozole to their recommended drugs for this group of women. By including this drug in their clinical guidelines, this important advancement in will provide greater protection from breast cancer for postmenopausal women at high risk of breast cancer."

Professor Mark Baker, director of the centre for guidelines at NICE, said: "Our draft guideline update recommends the use of anastrozole as a first line treatment for at high or medium risk of breast cancer who don't have osteoporosis.

"The evidence examined by the committee suggests anastrozole will not only reduce the number of breast cancer cases in these women compared to tamoxifen, but it is also a more cost effective option."

NICE's draft guideline update is out for consultation until 5 January 2017.

Explore further: Drug cuts breast cancer cases by more than 50 percent in high risk women

Related Stories

Drug cuts breast cancer cases by more than 50 percent in high risk women

December 12, 2013
Taking the breast cancer drug anastrozole for five years reduced the chances of post-menopausal women at high risk of breast cancer developing the disease by 53% compared with women who took a placebo, according to a study ...

Antihormone therapy anastrozole may provide new option for breast cancer prevention

December 12, 2013
Breast cancer incidence among postmenopausal women at high risk for developing the disease was significantly reduced by the antihormone therapy anastrozole, indicating that the drug may be an effective new option for breast ...

Anastrozole prevents recurrence more than tamoxifen in some with noninvasive breast cancer

June 1, 2015
Anastrozole provides a significant benefit compared with tamoxifen in preventing recurrence after a lumpectomy and radiation therapy in postmenopausal women ages 60 years or younger who had DCIS (ductal carcinoma in situ), ...

No significant differences in recurrence rates among women with DCIS taking anastrozole or tamoxifen

December 11, 2015
Postmenopausal women with ductal carcinoma in situ (DCIS) had similar outcomes with disease recurrence whether they took tamoxifen or the aromatase inhibitor anastrozole for five years after surgery, but women in the two ...

Drug provides another treatment option for an early form of breast cancer

December 11, 2015
The drug anastrozole is effective in treating an early form of breast cancer, according to a clinical trial led by Queen Mary University of London (QMUL). The results of the IBIS-II DCIS trial show that anastrozole is as ...

Breast cancer drug not recommended for use in England

September 4, 2017
The drug fulvestrant (Faslodex) has not been recommended in England to treat late stage breast cancer, in draft guidance.

Recommended for you

Scientists block the siren call of two aggressive cancers

January 23, 2018
Aggressive cancers like glioblastoma and metastatic breast cancer have in common a siren call that beckons the bone marrow to send along whatever the tumors need to survive and thrive.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.